Home

Jingrong Jean Cui

CIK 1772259 · President and CEO · last filed 2026-08-10

Jingrong Jean Cui is a President and CEO who has filed 24 SEC Form 4 insider transactions across 2 companies since 2019. The most recent filing, for BLSM, was dated Aug 10, 2026. Across all open-market trades the lifetime net is −$40.5M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

24

Lifetime Open-Market Net

-$40.48M

Filer Profile

Reported Address
C/O TURNING POINT THERAPEUTICS, INC.
10628 SCIENCE CENTER DR., STE. 225
SAN DIEGO, CA 92121
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BLSM President and CEO 2,667,803 — — $0 1 2026-08-10
Turning Point Therapeutics, Inc. (TPTX) Delisted Director 1,541,981 $76.01 $117.21M -$40.48M 23 2020-06-10

Recent Filings

24 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-10 BLSM Mixed +1,838,896 $0 EDGAR
2020-06-10 Turning Point Therapeutics, Inc. (TPTX) Delisted Sell (S) −9,500 -$625.2K EDGAR
2020-06-08 Turning Point Therapeutics, Inc. (TPTX) Delisted Sell (S) −55,500 -$3.56M EDGAR
2020-05-21 Turning Point Therapeutics, Inc. (TPTX) Delisted Sell (S) −21,000 -$1.24M EDGAR
2020-05-12 Turning Point Therapeutics, Inc. (TPTX) Delisted Sell (S) −11,500 -$619.4K EDGAR
2020-05-07 Turning Point Therapeutics, Inc. (TPTX) Delisted Sell (S) −55,500 -$2.96M EDGAR
2020-04-24 Turning Point Therapeutics, Inc. (TPTX) Delisted Sell (S) −21,000 -$1.08M EDGAR
2020-04-13 Turning Point Therapeutics, Inc. (TPTX) Delisted Sell (S) −12,208 -$581.1K EDGAR
2020-04-08 Turning Point Therapeutics, Inc. (TPTX) Delisted Sell (S) −55,500 -$2.49M EDGAR
2020-03-27 Turning Point Therapeutics, Inc. (TPTX) Delisted Sell (S) −11,500 -$529.4K EDGAR
Showing 1–10 of 24
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.